Oragenics Receives New Patent for Improved Replacement Therapy for Dental Caries
TAMPA, Fla.-- Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT – OGEN) today announced that it received U.S. patent protection for the next generation of SMaRT Replacement Therapy (SMaRT) including patent protection for live biotherapeutic compositions and methods for reducing the incidence of dental caries.
Specifically, the United States Patent and Trademark Office issued U.S. Patent No. 9,260,488 titled “Replacement Therapy for Dental Caries”, which provides Oragenics with seventeen years of patent protection for SMaRT for use in the prevention of tooth decay. The issued claims further protect several SMaRT pharmaceutical compositions and other delivery forms, including mouthwash, toothpaste, chewing gum, floss, chewable tablet, food, and beverage formulations.
“The SMaRT Replacement Therapy was designed to be a painless, one-time, five-minute topical treatment applied to the teeth that has the potential to offer lifelong protection against tooth decay,” stated Dr. Jeffrey D. Hillman, a co-inventor of this new SMaRT Technology, a co-Founder of Oragenics and retired Chief Science Officer of Oragenics. Dr. Hillman further commented: "I am thrilled that the improvements that we engineered in the SMaRT Therapy will afford Oragenics additional intellectual property which could enable us to attempt to demonstrate the safety and efficacy of this novel therapy in the clinic." Dr. Frederick Telling, Oragenics’ Chairman, said, “Dr. Hillman’s pioneering work continues to provide potentially new opportunities for improved healthcare and significant patient benefits.”
About Oragenics, Inc.
We are focused on becoming the world leader in novel antibiotics against infectious disease. We also develop, market and sell proprietary probiotics specifically designed to enhance oral health for humans and pets and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation Inc., a synthetic biology company. The collaborations allow Oragenics access to Intrexon's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. Oragenics also develops, markets and sells proprietary OTC probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora both in the United States and through the use of distributors in locations outside of the United States.
For more information about Oragenics, www.oragenics.com.
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, any inability to obtain or delays in FDA approval for future clinical studies and testing, the future success of our studies and testing and any inability to also achieve favorable results in human studies, our ability to successfully develop and commercialize products, the financial resources available to us to continue research and development, and those other factors described in our filings with the U.S. Securities and Exchange Commission. Any responsibility to update forward-looking statements is expressly disclaimed.
Michael Sullivan, 813-286-7900
Chief Financial Officer
The Ruth Group
Investor / Media Contacts
Stephanie Carrington, 646-536-7017/7028
Aaron Estrada, 646-536-7017/7028
Source: Oragenics, Inc.
Released February 19, 2016